Cagrilintide 10mg

Peptide Science research editorial team.

Cagrilintide 10mg Overview

Cagrilintide 10mg from Peptide Science is supplied as a lyophilised vial at 10 mg for in-vitro and preclinical adipose / metabolic research. Cagrilintide is a long-acting amylin-receptor analogue characterised in preclinical work for receptor-binding affinity and downstream incretin- or amylin-pathway signalling in pancreatic and adipose-tissue cell culture.

Receptor Profile and Class Background

Cagrilintide is a 32-amino-acid synthetic amylin-receptor analogue, designed for long-acting binding at the amylin receptor family (AMY1, AMY2, AMY3). Amylin is a 37-residue peptide co-secreted with insulin from pancreatic beta-cells, characterised in preclinical models for satiety-pathway and gastric-emptying signalling. Cagrilintide differs structurally from native amylin through targeted substitutions that improve in-vitro stability and receptor selectivity. Browse the broader metabolic peptide research range for adjacent compounds.

Specifications

For combined GLP-1 plus amylin research where both pathways are studied side-by-side, the Cagrilintide vial is commonly paired with Semaglutide 3mg in separate-vial co-administration protocols.

Reconstitution and Handling

The lyophilised vial reconstitutes with bacteriostatic water at the working concentration set by the principal investigator. Material is sensitive to repeated freeze-thaw cycles; aliquoting reconstituted stock for single-use frozen storage is the standard preclinical handling practice cited in incretin-research literature.

Quality and Shipping

Each batch passes HPLC at greater than 99 percent purity, with mass-spectrometry identity confirmation against the theoretical mass. A Certificate of Analysis accompanies every order. Material is filled in a US laboratory under ISO 9001:2015-aligned quality systems and dispatched in temperature-monitored insulated packaging via overnight or two-day courier.

For laboratory research and development use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease, including obesity or type 2 diabetes. Has not been evaluated by the U.S. Food and Drug Administration. Branded therapeutic GLP-1, GIP, and dual-agonist medicines (Ozempic, Wegovy, Mounjaro, Zepbound) are prescription-only medicines in the United States and are not the same as research-grade compounds supplied for in-vitro work. Purchasers acknowledge they are qualified researchers age 21 or older and accept responsibility for compliance with all applicable federal, state, and local laws.